Bolt Biotherapeutics, Inc.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $7.7M
- Net income
- -$33.4M
- Total assets
- $56.7M
- Market cap
- $8.8M
- Operating margin
- -469.3%
- Net margin
- -433.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $7.7M
- Operating expenses
- $43.8M
- Operating income
- -$36.1M
- Income tax
- $0
- Net income
- -$33.4M
- EPS (basic)
- $-17.85
- EPS (diluted)
- $-17.85
Balance sheet
- Total assets
- $56.7M
- Current assets
- $30.3M
- Total liabilities
- $30.2M
- Current liabilities
- $8.4M
- Shareholders’ equity
- $26.5M
Cash flow
- Operating cash flow
- -$39.9M
- Investing cash flow
- $44.3M
- Financing cash flow
- $19.0K
- Net cash flow
- $4.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $8.8M
- EPS (diluted)
- $-17.85
- Shares outstanding
- 2.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 5, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $33.4M in FY2025.
- Revenue grew 511% from FY2021 to FY2025.
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Bolt Biotherapeutics, Inc..
Write a review
News about Bolt Biotherapeutics, Inc.
News & sentiment via Polygon.io
